Abstract
Autoimmune diseases are a group of pathologies characterized by the presence of autoantibodies and the loss of immunological tolerance towards self-antigens. Although it is difficult to establish the incidence and prevalence, it is estimated that only 3% of the population in the United States suffers from any of them.
There are different therapeutic routes to tackle this class of diseases, highlighting biological therapies, one of them being monoclonal antibodies (MAbs). There are different therapeutic routes to address this class of diseases, highlighting biological therapies, one of them being monoclonal antibodies (MAbs). These are therapeutic agents with additional advantages in selectivity, availability and function related to small molecules and peptides. MABs are developed and approved for the treatment of diseases related to different systems such as nervous, cardiovascular, immunology, among others. This mini review summarizes the applications of monoclonal antibodies in autoimmune diseases with affections in the nervous system, focusing mainly on FDA approved monoclonal antibodies products that are currently available in the market.